In Luci Bonneau, breast cancer encountered the spirit of a woman who didn’t like to lose, a woman who discovered a new passion in the midst of a fight for her life. Luci was a talented bowler whose team broke a state record just months before she succumbed to breast cancer. “She kept bowling all the way to the end,” says former PWBA star Carol Norman, who won a PWBA regional event with Luci not long before that final tournament in Beaumont.
“Luci told me, ‘If I survive, we’ll put on a bowling tournament to raise money for breast cancer research,’” explained Donna Conners. But as with many of the 200,000 women diagnosed each year, Luci Bonneau did not survive breast cancer. Thanks to Donna and Luci’s many other friends in the bowling community, the disease that took this champion didn’t end her dream.
Today the Luci Bonneau Memorial Striking Against Breast Cancer Mixed Doubles Tournament attracts some of the country’s most talented bowlers and tournament administrators. It has become one of the most anticipated events on their calendars. As the tournament’s chosen charity, CHRISTUS Stehlin Foundation is honored to benefit from the event honoring this remarkable woman.
April 22, 2012
Combining a spirit of fun with a worthy philanthropic effort, Susan's Rally takes participants on an afternoon adventure in their automobiles and raises money for the fight against breast cancer!
“Dr. Stehlin has been right about cancer for more than 40 years . . . He achieved his remarkable success by carefully observing the behavior of cancer. He found order where others had only seen chaos. He found rules where others said there were no rules. And he spared hundreds of patients the disfiguring consequences of radical surgery.”
Dr. Richard Evans,
General Surgeon, 2007
The cancer drug bexarotene quickly eliminates Alzheimer's disease-associated amyloid beta from the brain and reverses memory problems in mice, a new study finds. The results suggest that bexarotene could help the 5.4 million Americans with Alzheimer's disease.
An international research team has made a breakthrough that could change the way pediatric cancers are treated in the future. The researchers identified two genetic mutations responsible for up to 40 per cent of glioblastomas in children.